Evidence map›Paper›PMID 39520590›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2025

Predictors of tolerability for postoperative adjuvant S1 plus docetaxel chemotherapy for gastric cancer: a multicenter retrospective study.

Kazuhiro Toyota, Kazuaki Tanabe, Mikihiro Kano, Toshiaki Komo, Ryuichi Hotta, Senichiro Yanagawa, Yoshihiro Saeki, Hirofumi Tazawa, Masahiro Ikeda, Masayuki Shishida and 6 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kazuhiro ToyotaDepartment of Surgery, Hiroshima Memorial Hospital, 1-4-3, Honkawa-cho, Naka-ku, Hiroshima, Hiroshima, 730-0802, Japan.
Kazuaki TanabeDepartment of Perioperative and Critical Care Management, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. ktanabe2@hiroshima-u.ac.jp.ORCID 0000-0002-8650-2735
Mikihiro KanoDepartment of Surgery, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan.
Toshiaki KomoDepartment of Surgery, JA Hiroshima General Hospital, Hatsukaichi, Japan.
Ryuichi HottaDepartment of Surgery, National Hospital Organization Higashihiroshima Medical Center, Higashihiroshima, Japan.
Senichiro YanagawaDepartment of Surgery, JA Onomichi General Hospital, Onomichi, Japan.
Yoshihiro SaekiDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hirofumi TazawaDepartment of Surgery, Kure Medical Center, Chugoku Cancer Center, Kure, Japan.
Masahiro IkedaDepartment of Surgery, Chuden Hospital, Hiroshima, Japan.
Masayuki ShishidaDepartment of Surgery, JR Hiroshima Hospital, Hiroshima, Japan.
Keisuke OkanoDepartment of Surgery, Miyoshi Central Hospital, Miyoshi, Japan.
Ryuta IdeDepartment of Surgery, Chugoku Rosai Hospital, Kure, Japan.
Yasuhiro ImaokaDepartment of Surgery, JA Yoshida General Hospital, Akitakata, Japan.
Shinya TakahashiDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Hideki OhdanDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdjuvant docetaxel plus S1 (DS) chemotherapy after gastrectomy with D2 lymph node dissection is the standard treatment for stage III gastric cancer in Japan; however, some patients are unable to receive adequate drug administration because of the deterioration of their conditions. This study aimed to investigate the correlation between tolerability for postoperative adjuvant DS chemotherapy and prognosis, and the factors affecting tolerability.

methodsThis retrospective study involved patients with stage III gastric cancer who underwent curative resection between 2018 and 2021 from a multicenter database. Patients with a cumulative dose of docetaxel and S1 greater than 120 and 8400 mg/m

resultsOf the 103 patients, the tolerable group comprised of 63 (61%) patients and had a significantly better 3-year recurrence-free survival than the intolerable group (83% vs. 64%, P = 0.02). Among the preoperative factors, only performance status (PS, P = 0.04) was significantly correlated with tolerability in the univariate analysis. Among the postoperative factors, PS (P = 0.001) and perioperative weight loss rate (P = 0.02) were significantly correlated with tolerability in the univariate analysis. The multivariate analysis showed significant differences in the PS (odds ratio [OR]: 4.94, 95% confidence interval [CI] 1.79-14.98, P = 0.002) and weight loss rate (OR: 1.10, 95% CI 1.01-1.21, P = 0.03).

conclusionsTolerance to postoperative adjuvant DS chemotherapy has a significant prognostic impact. Postoperative PS and perioperative weight loss rates were independent predictors of tolerability.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsDocetaxelDrug CombinationsGastrectomyOxonic AcidStomach NeoplasmsTegafurAdultAgedAged, 80 and overChemotherapy, AdjuvantFemaleHumansMaleMiddle AgedPrognosisDocetaxelDrug CombinationsOxonic AcidS 1 (combination)TegafurAdjuvant chemotherapyDocetaxelGastric cancerS1Tolerability

Identifiers

PMID39520590
PMCPMC11706876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.